Dysregulation of systemic immunity and its clinical application in gastric cancer DOI Creative Commons
Yao Zhang, Junfeng Li, Jian Li

et al.

Frontiers in Immunology, Journal Year: 2024, Volume and Issue: 15

Published: Sept. 5, 2024

Immunotherapy has profoundly changed the treatment of gastric cancer, but only a minority patients benefit from immunotherapy. Therefore, numerous studies have been devoted to clarifying mechanisms underlying resistance immunotherapy or developing biomarkers for patient stratification. However, previous focused mainly on tumor microenvironment. Systemic immune perturbations long observed in with and involvement peripheral system effective anticancer responses attracted much attention recent years. understanding distinct types systemic organization cancer will aid personalized designed pair traditional therapies alleviate their detrimental effects immunity directly activate response immunity. Herein, this review aims comprehensively summarize including induced by therapies, potential clinical applications detection, prediction, prognosis therapy cancer.

Language: Английский

lncRNAs as prognostic markers and therapeutic targets in cuproptosis-mediated cancer DOI Creative Commons
Asif Ahmad Bhat, Muhammad Afzal, Ehssan Moglad

et al.

Clinical and Experimental Medicine, Journal Year: 2024, Volume and Issue: 24(1)

Published: Sept. 26, 2024

Abstract Long non-coding RNAs (lncRNAs) have emerged as crucial regulators in various cellular processes, including cancer progression and stress response. Recent studies demonstrated that copper accumulation induces a unique form of cell death known cuproptosis, with lncRNAs playing key role regulating cuproptosis-associated pathways. These may trigger cell-specific responses to stress, presenting new opportunities prognostic markers therapeutic targets. This paper delves into the cuproptosis-mediated cancer, underscoring their potential biomarkers targets for innovative strategies. A thorough review scientific literature was conducted, utilizing databases such PubMed, Google Scholar, ScienceDirect, search terms like 'lncRNAs,' 'cuproptosis,' 'cancer.' Studies were selected based on relevance lncRNA regulation cuproptosis pathways implications prognosis treatment. The highlights significant contribution cuproptosis-related genes pathways, impacting metabolism, mitochondrial responses, apoptotic signaling. Specific are breast, lung, liver, ovarian, pancreatic, gastric cancers. objective this article is explore cancers mediated by cuproptosis.

Language: Английский

Citations

12
Comprehensive analysis and experimental validation of disulfidptosis-associated prognostic signature and immune microenvironment characterization of gastric cancer DOI Creative Commons

Huangjie Zhang,

Jinguo Hu,

Yuanqiang Li

et al.

Cancer Immunology Immunotherapy, Journal Year: 2025, Volume and Issue: 74(4)

Published: Feb. 25, 2025

Gastric cancer (GC) is one of the most common causes cancer-related death worldwide. As a novel form programmed cell death, disulfidptosis characterized by excessive cysteine accumulation, disulfide stress and actin destruction. There evidence that targeting promising anticancer strategy. Further improvement GC risk stratification based on has positive clinical significance. We analyzed expression levels disulfidptosis-associated genes (DPAGs) in normal tissues molecular subtypes patients. Based characteristics DPAG subtypes, differentially expressed prognosis-related were selected LASSO-univariate Cox analysis multivariate to establish prognostic model. Using single-cell sequencing reveals subpopulation for GC. The function target was verified vitro experimental means, including siRNA, qRT-PCR, Western blot, CCK-8, Transwell assay. score be an independent factor significantly associated with poor prognosis gastric cancer. Subsequent studies subgroup immunoinfiltration characteristics, drug sensitivity analysis, immunotherapy response somatic mutation comprehensively confirmed potential guiding significance individualized treatment Single-cell revealed DPAG-related signatures across subpopulations. In experiments showed APC11, as DPAGs, highly cancer, knockdown APC11 could inhibit proliferation migration cells, demonstrating reliability bioinformatics results. results this study provide new perspective exploring role occurrence development

Language: Английский

Citations

1
Application of immune checkpoint inhibitors for resectable gastric/gastroesophageal cancer DOI Creative Commons

Feizhi Lin,

Yongming Chen, Bowen Huang

et al.

Frontiers in Pharmacology, Journal Year: 2024, Volume and Issue: 15

Published: May 9, 2024

Gastric/gastroesophageal junction (G/GEJ) cancer represents a significant global health challenge. Radical surgery remains the cornerstone of treatment for resectable G/GEJ cancer. Supported by robust evidence from multiple clinical studies, therapeutic approaches, including adjuvant chemotherapy or chemoradiation, and perioperative chemotherapy, are generally recommended to reduce risk recurrence enhance long-term survival outcomes post-surgery. In recent years, immune checkpoint inhibitors (ICIs) have altered landscape systemic advanced metastatic cancer, becoming standard first-line therapy specific patients. Consequently, exploring efficacy ICIs in neoadjuvant setting is worthwhile. This review summarizes current advances application

Language: Английский

Citations

4
Efficacy and safety of nivolumab plus ipilimumab in gastrointestinal cancers: a systematic review and meta-analysis DOI Creative Commons
Bowen Dai,

Jiaping Jiang,

Xiaoyu Yu

et al.

Frontiers in Oncology, Journal Year: 2025, Volume and Issue: 14

Published: Jan. 7, 2025

Gastrointestinal (GI) cancers represent a significant global health burden, and the need for more effective treatment options is exceptionally pressing. The present meta-analysis aimed to explore efficacy safety of combination nivolumab ipilimumab in treating GI cancers. A systematic search four databases (PubMed, Embase, Web Science, Cochrane Library) was conducted articles on with combined ipilimumab, published from 2014 up 30 August 2024. inclusion criteria were designed according principles Participants, Intervention, Control, Outcomes, Study (PICOS). control group chemotherapy or monotherapy other drugs. We extracted data 10 randomized controlled trials utilized random effects model assess objective response rate (ORR), median progression-free survival (mPFS), overall (mOS), duration (mDOR), treatment-related adverse events (TRAEs). analysis using Review Manager version 5.4 Stata 12.0. Overall, demonstrated superior outcomes, including higher ORR (OR = 1.69, P 0.01), prolonged mOS (MD 1.74, 0.04) extended mDOR 5.64, < 0.00001) compared group. Subgroup that 1.75, 0.02) 5.02, 0.003) significantly improved patients esophageal cancer. Notably, biliary cancer lower 0.11, 0.04). Additionally, NIVO1 + IPI3group 2.82, 0.01) NIVO3 IPI1 1.62, 0.01). Regarding safety, there no statistically difference between regimen terms any grade 0.72, 0.26) 3-4 TRAEs 1.36, 0.14). Nivolumab (especially cancer) without causing reactions. However, its still needs be further proven. https://www.crd.york.ac.uk/prospero/, identifier CRD42024590994.

Language: Английский

Citations

0
Actinidia eriantha polysaccharide prevents gastric cancer invasion and metastasis via inhibition of PD-1/PD-L1 regulation of macrophage polarization DOI Creative Commons
Jinxia Li, Kun Gao, Ying Liu

et al.

International Journal of Biological Macromolecules, Journal Year: 2025, Volume and Issue: 304, P. 140763 - 140763

Published: Feb. 6, 2025

Language: Английский

Citations

0
Deciphering the Role of DNA Methylation-Driven Genes in Rectal Cancer: Insights into Prognostic Modeling and Mechanistic Pathways DOI Creative Commons
Weipeng Liu,

Lugao Tian,

Weiwei Wei

et al.

Research Square (Research Square), Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 14, 2025

Abstract Background DNA methylation alterations play a crucial role in rectal cancer development. This study identifies and characterizes methylation-driven genes the TCGA-READ cohort, exploring their association with development underlying mechanism. Methods were identified using MethylMix package subjected to gene ontology (GO) enrichment analysis via cluster profiler package. Prognostic model involved Lasso regression ten-fold cross-validation, followed by performance evaluation Kaplan-Meier survival curves, time-dependent ROC calibration decision curve analysis. Cancer-promoting mechanism high risk score group was clarified through set (GSEA) multi-algorithm-based immune infiltration analyses. Results GO highlighted significant functional terms based on 490 genes, implicating Wnt signaling cell fate commitment The developed prognostic model, consisting of CCNI2, LINC00899, ST6GALNAC1, exhibited predictive accuracy. Differential expression 89 underexpressed high-risk group, SULF1 as hub gene. negative regulation process malignant tumor-associated pathways is suppressed, decreased abundance cytotoxic cells, such NK may represent potential for poor prognosis observed group. Conclusions Our findings elucidate landscape cancer. These insights contribute deeper understanding progression provide targets therapeutic intervention.

Language: Английский

Citations

0
Gastrointestinal cancer: Current status of preclinical research DOI
Nariman Shahid, Sana Hanif,

Muhammad Ali Syed

et al.

Elsevier eBooks, Journal Year: 2025, Volume and Issue: unknown, P. 317 - 348

Published: Jan. 1, 2025

Language: Английский

Citations

0
Pathologic complete response after Sintilimab combined with FOLFOX therapy in MSI-H type patients with locally advanced GC: a case report DOI Creative Commons
Peijian Wang,

Yuanhui Gu,

Yi Lin

et al.

Frontiers in Oncology, Journal Year: 2025, Volume and Issue: 15

Published: May 8, 2025

As one of the most common gastrointestinal tumors, Gastric Cancer (GC) poses a serious threat to human health due its high morbidity and mortality. The current treatment strategy is comprehensive program mainly based on surgery, especially for advanced GC patients. emergence immune checkpoint inhibitors has completely changed this status quo, synergistic effect neoadjuvant immunotherapy combined with chemotherapy significantly improved resection radical rate overall survival patients local GC. We present case locally (cT4N0Mx) microsatellite instability (MSI-H) PD-L1 Combined Positive Score (CPS)=2. patient received therapy Sintilimab FOLFOX (folinic acid (leucovorin), 5-fluorouracil (5-FU), oxaliplatin), reduced tumor volume after 3 cycles treatment. Then she underwent subtotal gastrectomy gastrojejunostomy D2 lymph node dissection. postoperative pathological results showed that no cancerous tissue remained in tissue, pathologic complete response (pCR) was achieved. first cycle adjuvant same protocol surgery. During therapy, experienced side effects such as dyspepsia, nausea mild myelosuppression. Therefore, potential be an effective option resectable MSI-H

Language: Английский

Citations

0
A Novel Telomere Maintenance Gene-Related Model for Prognosis Prediction in Gastric Cancer DOI Creative Commons
Keliang Wang, Xiao-xia Xi, Jie Zheng

et al.

Biochemical Genetics, Journal Year: 2025, Volume and Issue: unknown

Published: May 20, 2025

Language: Английский

Citations

0
Circular RNA Circ_0000119 promotes gastric cancer progression via circ_0000119/miR-502-5p/MTBP axis DOI
Mengyan Xie, Yunru Gu, Tingting Xu

et al.

Gene, Journal Year: 2024, Volume and Issue: 908, P. 148296 - 148296

Published: Feb. 18, 2024

Language: Английский

Citations

3